Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 635

Prevention of Chronic Allograft Rejection Using Angiogenesis Inhibitors

Inventors: David Briscoe, Karen Moulton, Mohamed Sayegh

Invention Types: Therapeutics

Research Areas: Cardiovascular/Cardiology, Immunology, Internal Medicine

Keywords: Anti-angiogenesis, New Indication/Use, Organ Transplant, Transplantation

For More Information Contact:  Caron, Connie

 

Invention Description:

Investigators at Children's Hospital Boston have shown in vivo that treatment of an organ donor and/or transplant recipient with angiogenesis inhibitors such as TNP-470 or AGM 1470 decreased chronic organ rejection in the recipient. The vascular endothelium participates in the initiation of graft arteriosclerosis lesions, the characteristic lesion of chronic allograft rejection. Despite advances in techniques for immunosuppression and tissue typing, early ischemia reperfusion injury and acute and chronic transplant rejection remain a serious clinical problem only partially controlled by current immunosuppressive drugs. Current treatments are also associated with the detrimental side effects resulting from impaired immune system function.

Applications:

Chronic allograft rejection in organ transplantation

Competitive Advantages:

Angiogenesis inhibitors can be administered alone or together with traditional immunosuppression agents, and combination treatment could potentially decrease the risk of the detrimental side-effects associated with the addition of immunosuppressive agents.

Business Opportunity:

Exclusive or Non-Exclusive License

Key Publications: Transplantation. 2004 Oct 27;78(8):1218-21.|

J Am Soc Nephrol. 2006 Apr;17 |

J Clin Invest. 2003 Dec;112(11):1655-65.(4):932-42.

Related Publications: US patent number: 6,218,361

IPStatus: Patented